Cytomegalovirus in Pregnancy: Effects on the Developing Embryo and Fetus, Diagnosis and Treatment: Where to Go Now? A Narrative Review
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms27010252 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Asher Ornoy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Adelson School of Medicine, Ariel University, Ariel 40700, Israel. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Pregnancy Complications, Infectious, Cytomegalovirus, Fetus. Die Arbeit nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cytomegalovirus (CMV) is the most common infectious cause of congenital malformations, often presenting with atypical clinical findings. Fetal damage is most severe following primary maternal infection during the first trimester of pregnancy, with the likelihood of transmission increasing with pregnancy advancement. CMV damage may continue to intensify during the early postnatal years. In this narrative review we summarized publications from the last 30 years addressing the epidemiology, diagnosis, prevention and treatment of CMV in pregnancy, with a special emphasis on embryonic and fetal damage. Substantial progress has been made in the diagnosis and treatment of CMV infection during pregnancy, warranting a reconsideration of current clinical approaches. Assessment of viral load enables prediction of fetal infection; its reduction by maternal treatment with valacyclovir may lower both the rate and severity of transmission. Confirmed fetal infection can be diagnosed by amniocentesis and viral DNA detection. Clinical manifestations in infants may be evident at birth (cCMV) or gradually emerge during the first years. The most common fetal damage is hearing loss alongside a variety of brain lesions resulting in significant neurological deficits, including intellectual impairment. Brain involvement is diagnosed by ultrasound or magnetic resonance imaging (MRI). Pharmacological treatment with ganciclovir or valganciclovir, if initiated early after birth, can slow the progression of hearing loss and may ameliorate other neurological and neurodevelopmental deficits. As of today, there is no approved CMV vaccine for prevention. The mRNA-1647’s vaccine, currently in phase 3 clinical trial, appears promising. These advances underscore the need for screening pregnant women in the first trimester and newborn infants of mothers suspected of having CMV infection. Neurodevelopmental follow up for several years, including hearing and visual assessment, is advised in all infants positive for CMV. Infants with clinical manifestations should be offered treatment as early as possible following diagnosis of cCMV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Adelson School of Medicine, Ariel University, Ariel 40700, Israel.
- Program for the Development of Children with Special Needs, Jerusalem Multidisciplinary College, Jerusalem 9422408, Israel.
- Department of Medical Neurobiology, Hebrew University Hadassah Medical School, Jerusalem 91120, Israel.
ORCID-Profile: Asher Ornoy
Zitieren
APA
Ornoy, A., & Weinstein-Fudim, L. (2025). Cytomegalovirus in Pregnancy: Effects on the Developing Embryo and Fetus, Diagnosis and Treatment: Where to Go Now? A Narrative Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010252
Vancouver
Ornoy A, Weinstein-Fudim L. Cytomegalovirus in Pregnancy: Effects on the Developing Embryo and Fetus, Diagnosis and Treatment: Where to Go Now? A Narrative Review. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms27010252
BibTeX
@article{Ornoy2025,
author = {Ornoy, Asher and Weinstein-Fudim, Liza},
title = {Cytomegalovirus in Pregnancy: Effects on the Developing Embryo and Fetus, Diagnosis and Treatment: Where to Go Now? A Narrative Review},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms27010252}
}
EUVIMED